Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$507.36 USD

507.36
189,566

+1.02 (0.20%)

Updated Nov 4, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.

    Hologic Launches Fluent Fluid Management System, Widens Suite

    Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

      Here's Why You Should Invest in Align Technology (ALGN) Now

      We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.

        AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

        AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

          Wright Medical Strong Overseas, Back Order Issues Persist

          Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.

            Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

            Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.

              Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

              Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.

                Inogen's Solid Europe Business Shapes Q2, Prospects Bright

                Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.

                  Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes

                  Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.

                    Becton, Dickinson Global Foothold Strong, Recalls Rampant

                    Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.

                      Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?

                      Is (ISRG) Outperforming Other Medical Stocks This Year?

                        STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

                        STERIS (STE) continues to gain from strength in all business segments in Q1.

                          Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells

                          Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.

                            Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates

                            Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.

                              OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2

                              OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.

                                Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View

                                Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.

                                  Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2

                                  Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.

                                    CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up

                                    CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.

                                      BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top

                                      A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.

                                        Allscripts Gains From Strong Results in Q2, Competition Rife

                                        Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.

                                          Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up

                                          Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.

                                            Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance

                                            Inogen (INGN) puts up solid segmental show in Q2; international sales surge.

                                              Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

                                              Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                                                Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish

                                                Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.

                                                  DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance

                                                  DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.